首页> 外文期刊>Revista Brasileira de Hematologia e Hemoterapia >Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations
【24h】

Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations

机译:原发性结节性外周T细胞淋巴瘤:诊断和治疗考虑

获取原文
           

摘要

Nodal peripheral T-cell lymphomas are a rare group of neoplasms derived from post-thymic and activated T lymphocytes. A review of scientific articles listed in PubMed, Lilacs, and the Cochrane Library databases was performed using the term "peripheral T-cell lymphomas". According to the World Health Organization classification of hematopoietic tissue tumors, this group of neoplasms consists of peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma-anaplastic lymphoma kinase positive (ALCL-ALK+), and a provisional entity called anaplastic large cell lymphoma-anaplastic lymphoma kinase negative (ALCL-ALK-). Because the treatment and prognoses of these neoplasms involve different principles, it is essential to distinguish each one by its clinical, immunophenotypic, genetic, and molecular features. Except for anaplastic large cell lymphoma-anaplastic lymphoma kinase positive, which has no adverse international prognostic index, the prognosis of nodal peripheral T-cell lymphomas is worse than that of aggressive B-cell lymphomas. Chemotherapy based on anthracyclines provides poor outcomes because these neoplasms frequently have multidrug-resistant phenotypes. Based on this, the current tendency is to use intensified cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) regimens with the addition of new drugs, and autologous hematopoietic stem cell transplantation. This paper describes the clinical features and diagnostic methods, and proposes a therapeutic algorithm for nodal peripheral T-cell lymphoma patients.
机译:淋巴结周围性T细胞淋巴瘤是一类罕见的肿瘤,其来源于胸腺后和活化的T淋巴细胞。使用术语“外周T细胞淋巴瘤”对PubMed,丁香和Cochrane图书馆数据库中列出的科学文章进行了综述。根据世界卫生组织对造血组织肿瘤的分类,这组肿瘤由未另作说明的外周T细胞淋巴瘤(PTCL-NOS),血管免疫母细胞性T细胞淋巴瘤(AITL),间变性大细胞淋巴瘤-间变性淋巴瘤激酶阳性(ALCL-ALK +)和称为间变性大细胞淋巴瘤-间变性淋巴瘤激酶阴性(ALCL-ALK-)的临时实体。由于这些肿瘤的治疗和预后涉及不同的原则,因此必须通过其临床,免疫表型,遗传和分子特征来区分每个肿瘤。除间变性大细胞淋巴瘤-间变性淋巴瘤激酶阳性(无不良国际预后指标)外,淋巴结周围性T细胞淋巴瘤的预后较侵袭性B细胞淋巴瘤差。基于蒽环类药物的化学疗法治疗效果较差,因为这些肿瘤经常具有多药耐药表型。基于此,当前的趋势是使用增强的环磷酰胺,阿霉素,长春新碱,泼尼松龙(CHOP)方案并添加新药物,以及自体造血干细胞移植。本文描述了其临床特点和诊断方法,并提出了一种针对淋巴结周围性T细胞淋巴瘤患者的治疗算法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号